Lorenzo Zaffiri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lorenzo Zaffiri has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Laurie D. Snyder
Division of Pulmonary Allergy and Critical Care Medicine Department of Medicine Duke University Medical Center Durham North Carolina USA
7 shared publications Pedro Catarino
4 shared publicationsDarina Barnes
Department of Pulmonary and Critical Care Medicine Cedars‐Sinai Medical Center Los Angeles California USA
3 shared publicationsMegan L. Neely
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
3 shared publicationsReinaldo Rampolla
Department of Pulmonary and Critical Care Medicine Cedars‐Sinai Medical Center Los Angeles California USA
3 shared publications- Reinaldo Rampolla
Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, United States
3 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (11) , 1871-1876
Mapping the mTOR pathway in lung transplantation: Is it time for a biomarker-driven precision therapy?
- 13 July 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (11) , 1871-1876
Open AccessMapping the mTOR pathway in lung transplantation: Is it time for a biomarker-driven precision therapy?
- 30 December 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (2) , e70164
Lung Transplantation in People Living With HIV With Absolute CD4+ T Cell Counts Under 200 Cells per Microliter
- 30 December 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 28 (2) , e70164
Lung Transplantation in People Living With HIV With Absolute CD4+ T Cell Counts Under 200 Cells per Microliter
- 2 February 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (8) , 1358-1366
Impact of minimally invasive lung transplantation on early outcomes and analgesia use: A matched cohort study
- 2 February 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (8) , 1358-1366
Impact of minimally invasive lung transplantation on early outcomes and analgesia use: A matched cohort study
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1993. Donor-Derived Transmission of Candida species: 10-year Analysis from the OPTN ad hoc Disease Transmission Advisory Committee (DTAC)
Solid organ transplantation (SOT) is lifesaving, but donor-derived infections can be associated with significant morbidity and mortality. Candida species are common colonizers in deceased donors managed in the intensive care environment, and transmission to the recipient through transplantation is a described phenomenon. We sought to characterize Candida transmission events in the US SOT population. Cases referred to Organ Procurement and Transplantation Network (OPTN) Disease Transmission Advisory Committee (DTAC) between 2012 and 2022 as potential donor disease transmission events (PDDTE) were adjudicated by DTAC based on consensus definitions. We included all recipients from any donor in which ≥1 proven or probable (P/P) or possible transmission of Candida occurred. Donor-derived Candida infections occur with significant associated morbidity, including graft loss, and mortality, especially in kidney recipients. Opportunity exists to further identify risks, improve communication across transplant centers, initiate appropriate antifungal therapy, and improve management of mycotic aneurysm due to candidiasis. Jason D. Goldman, MD, MPH, Adaptive Biotechnologies: Collaborative services agreements|Eli Lilly: Advisor/Consultant|Eli Lilly: Grant/Research Support|Eli Lilly: Honoraria|Gilead Sciences: Advisor/Consultant|Gilead Sciences: Grant/Research Support|Gilead Sciences: Honoraria|GSK: Advisor/Consultant|Karius, Inc.: Advisor/Consultant|Merck: Grant/Research Support|Monogram Biosciences / Labcorp: Collaborative services agreements|Regeneron: Grant/Research Support Anil J. Trindade, MD, CareDx, Inc.: Advisor/Consultant|CareDx, Inc.: Grant/Research Support|Veloxis Pharmaceuticals, Inc.: Grant/Research Support Ricardo M. La Hoz, MD, Takeda: Advisor/Consultant Lara A. Danziger-Isakov, MD, MPH, Aicuris: Contracted Clinical Research|Ansun Biopharma: Contracted Clinical Research|Astellas: Contracted Clinical Research|GSK: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Contracted Clinical Research|Pfizer: Contracted Clinical Research|Roche Diagnostics: Advisor/Consultant|Takeda: Advisor/Consultant|Takeda: Contracted Clinical Research
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1993. Donor-Derived Transmission of Candida species: 10-year Analysis from the OPTN ad hoc Disease Transmission Advisory Committee (DTAC)
Solid organ transplantation (SOT) is lifesaving, but donor-derived infections can be associated with significant morbidity and mortality. Candida species are common colonizers in deceased donors managed in the intensive care environment, and transmission to the recipient through transplantation is a described phenomenon. We sought to characterize Candida transmission events in the US SOT population. Cases referred to Organ Procurement and Transplantation Network (OPTN) Disease Transmission Advisory Committee (DTAC) between 2012 and 2022 as potential donor disease transmission events (PDDTE) were adjudicated by DTAC based on consensus definitions. We included all recipients from any donor in which ≥1 proven or probable (P/P) or possible transmission of Candida occurred. Donor-derived Candida infections occur with significant associated morbidity, including graft loss, and mortality, especially in kidney recipients. Opportunity exists to further identify risks, improve communication across transplant centers, initiate appropriate antifungal therapy, and improve management of mycotic aneurysm due to candidiasis. Jason D. Goldman, MD, MPH, Adaptive Biotechnologies: Collaborative services agreements|Eli Lilly: Advisor/Consultant|Eli Lilly: Grant/Research Support|Eli Lilly: Honoraria|Gilead Sciences: Advisor/Consultant|Gilead Sciences: Grant/Research Support|Gilead Sciences: Honoraria|GSK: Advisor/Consultant|Karius, Inc.: Advisor/Consultant|Merck: Grant/Research Support|Monogram Biosciences / Labcorp: Collaborative services agreements|Regeneron: Grant/Research Support Anil J. Trindade, MD, CareDx, Inc.: Advisor/Consultant|CareDx, Inc.: Grant/Research Support|Veloxis Pharmaceuticals, Inc.: Grant/Research Support Ricardo M. La Hoz, MD, Takeda: Advisor/Consultant Lara A. Danziger-Isakov, MD, MPH, Aicuris: Contracted Clinical Research|Ansun Biopharma: Contracted Clinical Research|Astellas: Contracted Clinical Research|GSK: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Contracted Clinical Research|Pfizer: Contracted Clinical Research|Roche Diagnostics: Advisor/Consultant|Takeda: Advisor/Consultant|Takeda: Contracted Clinical Research
- 21 October 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (11) , 2316-2328
Screening and Management of PTLD
Posttransplant lymphoproliferative disorder (PTLD) represents a heterogeneous group of lymphoproliferative diseases occurring in the setting of immunosuppression following hematopoietic stem cells transplant and solid organ transplantation. Despite its overall low incidence, PTLD is a serious complication following transplantation, with a mortality rate as high as 50% in transplant recipients. Therefore, it is important to establish for each transplant recipient a personalized risk evaluation for the development of PTLD based on the determination of Epstein-Barr virus serostatus and viral load following the initiation of immunosuppression. Due to the dynamic progression of PTLD, reflected in the diverse pathological features, different therapeutic approaches have been used to treat this disorder. Moreover, new therapeutic strategies based on the administration of virus-specific cytotoxic T cells have been developed. In this review, we summarize the available data on screening and treatment to suggest a strategy to identify transplant recipients at a higher risk for PTLD development and to review the current therapeutic options for PTLD.
- 21 October 2023
- Published by Wolters Kluwer Health in Transplantation
- Vol. 107 (11) , 2316-2328
Screening and Management of PTLD
Posttransplant lymphoproliferative disorder (PTLD) represents a heterogeneous group of lymphoproliferative diseases occurring in the setting of immunosuppression following hematopoietic stem cells transplant and solid organ transplantation. Despite its overall low incidence, PTLD is a serious complication following transplantation, with a mortality rate as high as 50% in transplant recipients. Therefore, it is important to establish for each transplant recipient a personalized risk evaluation for the development of PTLD based on the determination of Epstein-Barr virus serostatus and viral load following the initiation of immunosuppression. Due to the dynamic progression of PTLD, reflected in the diverse pathological features, different therapeutic approaches have been used to treat this disorder. Moreover, new therapeutic strategies based on the administration of virus-specific cytotoxic T cells have been developed. In this review, we summarize the available data on screening and treatment to suggest a strategy to identify transplant recipients at a higher risk for PTLD development and to review the current therapeutic options for PTLD.
- 1 August 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (5) , 1054-1055
Lung Transplant From Coronavirus Disease 2019–Positive Donors: Cautiously Optimistic
- 1 August 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (5) , 1054-1055
Lung Transplant From Coronavirus Disease 2019–Positive Donors: Cautiously Optimistic
- 20 July 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (12) , 1690-1699
Lung transplantation outcomes in patients from socioeconomically distressed communities
- 20 July 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (12) , 1690-1699
Lung transplantation outcomes in patients from socioeconomically distressed communities